Saxsons Group — India's trusted nuclear medicine, radiotherapy, oncosurgery, dosimetry and cyclotron supplier since 1986

myOSL™ Chip — what the literature says.

Two independent 2025 peer-reviewed studies — Kowalski et al. (Duke) and Davis et al. (UVA), both in the Journal of Applied Clinical Medical Physics — characterise the BeO myOSL Chip and show it meeting or beating a discontinued Al2O3:C reference OSL chip in every clinical modality tested.

2 / 2independent 2025 validation studies
−0.5%→+3%linearity across 0.1 – 20 Gy
+1.72%TBI difference vs the discontinued Al2O3:C reference chip — within tolerance
Product specsPhysicist's dossier

Product page — myOSL™ Chip

myOSL™ Chip specifications, brochure and quote request

Technical specifications, application notes, AERB compliance documentation and direct quote request for myOSL™ Chip. Ships from Saxsons Group — 1,000+ Indian hospitals for 40 years.

Review the myOSL™ Chip specifications
Independent evidence

Published studies using myOSL™ Chip

Peer-reviewed studies that measured myOSL™ Chip directly, with the key result from each paper's abstract. The quoted line shows where the paper names myOSL™ Chip.

Journal of applied clinical medical physics · 2025· Cited 5×· QA & dosimetry

Linearity corrections -0.5% to +3% over 0.1–20 Gy; no dose-rate dependence over 100–2500 MU/min; equal or superior to aluminum oxide OSLs clinically.

Characterization, commissioning, and clinical evaluation of a commercial BeO optically stimulated luminescence (OSL) system.

Kowalski JP, Erickson BG, Wu Q et al.

“This article investigates the performance of a commercial BeO optically stimulated luminescent (OSL) dosimetry system (myOSLchip) through the application of the commissioning framework for luminescent dosimeters as described in the American Association of Physicists in …”
Paper details →Read free →
Filter
Commissioning metrics — myOSL Chip
−0.5%→+3%
Linearity 0.1–20 Gy
±4.5%
Photon kQ vs 6 MV
flat
100–2500 MU/min
Linearity correction factors stayed within −0.5% to +3% across 0.1–20 Gy. No dose-rate dependence observed across the full clinical range.
Characterisation2025
≤ ±4.5%beam-quality correction across 2.5 MV FFF to 15 MV — flat dose-rate response 100–2500 MU/min

Characterization, commissioning, and clinical evaluation of a commercial BeO optically stimulated luminescence (OSL) system

Journal of Applied Clinical Medical Physics 26(4):e70057 — Kowalski, Erickson, Wu, Li, Yoo (Duke)

Angular response (6 MV photons)
Baseline
En-face (0°)
reference orientation
vs
−2.02% ± 0.45%
Edge-on (90°)
within typical in-vivo bracket
Characterisation2025
−2.02%± 0.45% signal decline at 90° vs en-face — bounds the in-vivo placement correction

Angular response of the myOSL Chip vs en-face (6 MV)

Kowalski et al., JACMP 2025 26(4):e70057

Read-out depletion behaviour
−2.13%
avg / readout
−2.6%
first readout
+5%
5-min fade peak
Transient signal enhancement has a 1.8-min half-life — measurement protocols time the read accordingly (1 % residual by 15 min, 0 % by 24 h).
Characterisation2025
−2.13%± 0.20% average signal loss per readout — characterised, predictable, correctable

Signal depletion per readout — characterised correction

Kowalski et al., JACMP 2025 26(4):e70057

Modality-by-modality vs Al2O3:C reference OSL chip
=
TBI in-vivo
=
TSET en-face
=
Electrons 6–20 MeV
=
Pacemaker / OOF
Equal-or-superior performance across every modality tested — clinics can drop in the myOSL Chip without redesigning their TG-191 in-vivo workflow.
vs Al2O3:C reference2025
Equal/superiormyOSL Chip matched or beat the discontinued Al2O3:C reference OSL chip across TBI, TSET, electrons and out-of-field measurements

Clinical validation of myOSLchip: A beryllium oxide optically stimulated luminescent dosimeter (OSLD) system in radiotherapy dosimetry

Journal of Applied Clinical Medical Physics — Davis, Siebers, Wijesooriya, Mistro (UVA)

TBI: myOSL Chip vs Al2O3:C reference OSL chip
Reference
Al2O3:C reference OSL chip
discontinued alternative product
vs
+1.72% ± 2.73%
myOSL Chip (BeO)
inside the in-vivo tolerance band
vs Al2O3:C reference2025
+1.72%± 2.73% mean difference vs the discontinued Al2O3:C reference chip in TBI — within in-vivo measurement tolerance

TBI in-vivo comparison — myOSL Chip vs the discontinued Al2O3:C reference OSL chip

Kowalski et al., JACMP 2025 (cross-validation of Davis 2025)

Back to myOSL Chip product page

myOSL™ Chip

More for this product

Each card opens a focused post for a specific specialty — clinical workflow and evidence, written for the persona you select.

For Medical Physicist

Medical Physicist

Type-test dossier

Linearity to 10 Sv, fading at 3 months, energy & angular response — the manufacturer type-test data in one page.

Read thisMedical Physicist

myOSL Chip vs MOSFET dosimeters

MOSFETs need replacement every 200–400 Gy and most readers max out at 5 channels per module. What changes when you switch to BeO OSL?

Read thisMedical Physicist

Why BeO OSL fits TBI dosimetry

TBI needs 8–10+ in-vivo points across a long fraction. Where does the myOSL Chip line up with the workflow — and what does the peer-reviewed evidence say?

Read this

Literature Radar · auto-updated daily

Latest OSL dosimetry research

Fresh peer-reviewed papers on optically-stimulated luminescence dosimetry, auto-updated from Europe PMC.

See all in radar →
Get the weekly digest →